arrow
B

Bernard M.J. Uitdehaag

vrije universiteit amsterdam
H指数:83
被引数:3.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The predictive value of serum neurofilament light chain levels beyond MRI measures for clinical and radiological disease progression in the earliest stages of multiple sclerosis

血清神经丝轻链水平对多发性硬化最早阶段临床和影像学疾病进展的预测价值,超越MRI测量

2026-09-090
OAAI
Treatment satisfaction during personalized extended interval dosing of natalizumab in patients with multiple sclerosis

多发性硬化患者个性化延长间隔给药方案下纳武利尤单抗的治疗满意度

2026-07-010
PRE
The Effect of Use of Tricyclic Antidepressants or Serotonin-Norepinephrine Reuptake Inhibitors Versus Selective Serotonin Reuptake Inhibitors on the Risk of Urinary Tract Infection Among People With Multiple Sclerosis: A Nested Case-Control Study

三环类抗抑郁药或血清素-去甲肾上腺素再摄取抑制剂与选择性血清素再摄取抑制剂对多发性硬化症患者尿路感染风险的影响:一项巢式病例对照研究

2025-11-060
OAAI
Reliability of serum neurofilament light and glial fibrillary acidic protein for detecting disease activity upon discontinuation of first-line disease-modifying therapy in stable multiple sclerosis (DOT-MS)

血清神经丝蛋白轻链和胶质纤维酸性蛋白在稳定型多发性硬化(DOT-MS)中停用一线疾病修饰疗法后检测疾病活动的可靠性

2025-07-230
OAAI
Cognitive test performance and disease progression in primary and secondary progressive MS: An analysis of the SPRINT-MS study

认知测试表现和疾病进展在原发进展型与继发进展型多发性硬化中的比较:一项对SPRINT-MS研究的分析

2025-05-080
PRE
Low natalizumab trough concentrations are associated with reduced seroconversion of the John Cunningham virus in natalizumab-treated patients with multiple sclerosis
2025-03-010
PRE
Serum neurofilament light and glial fibrillary acidic protein levels are not associated with wearing-off symptoms in natalizumab-treated multiple sclerosis patients
2024-11-041
OAAI
Instrumental activities of daily living in neuro-oncology: International validation of the EORTC IADL-BN32 questionnaire
2024-11-011
OAAI
Impact of serum neurofilament light on clinical decisions in a tertiary multiple sclerosis clinic
2024-10-171
OAAI